Nuclear Medicine Therapeutics Market: Developments and Outlook 2030
Added: (Tue May 09 2023)
Pressbox (Press Release) -
Nuclear Medicine Therapeutics Market: Developments and Outlook
Nuclear medicine has been increasingly prevalent in healthcare throughout time, notably in the realm of cancer therapy. Nuclear medicine therapy uses radioactive substances, or radioisotopes, to treat a variety of illnesses include cancer, thyroid problems, and bone pain. In the upcoming years, the market for nuclear medicine treatments is anticipated to expand as a result of developments in imaging technology and the creation of novel radioisotopes with therapeutic applications.
The global market for nuclear medical therapies is anticipated to expand between 2023 and 2030 at a compound annual growth rate (CAGR) of around 8%, according to a research by Pharamanucleus. The research identifies a number of reasons, including rising prevalence, as the cause of this development.
Iodine-131, which is used to treat thyroid cancer and hyperthyroidism, is one of the radioisotopes that is most frequently utilised in nuclear medicine therapy. The treatment of bone metastases, neuroendocrine tumours, and prostate cancer also uses other radioisotopes as radium-223, lutetium-177, and yttrium-90. To offer focused treatment and enhance patient outcomes, these radioisotopes are frequently employed in conjunction with imaging methods like positron emission tomography (PET) and single photon emission computed tomography (SPECT).
It takes specific knowledge and equipment to utilise radioactive elements for medical reasons, and the market for nuclear medicine therapies is heavily controlled. The market is anticipated to expand despite these difficulties because of the rising incidence of cancer and the demand for more efficient treatment alternatives.
In recent years, there have been significant advancements in nuclear medicine imaging technology, which has led to improved diagnosis and treatment of cancer. For example, theranostics is a new field of nuclear medicine that combines therapy and diagnostics. It involves the use of radioisotopes to both diagnose and treat cancer, allowing for more personalized and targeted treatment options.
The market for nuclear medicine therapeutics is also seeing increased investment in research and development from key players in the industry. Companies such as Novartis International AG, Bayer AG, Cardinal Health, Inc., GE Healthcare, and Curium are investing heavily in developing new radioisotopes and improving imaging technology to provide better diagnosis and treatment options for patients.
In conclusion, the nuclear medicine therapeutics market is expected to continue to grow in the coming years, driven by advancements in imaging technology and the development of new radioisotopes for therapeutic use. With increasing investment in research and development, the field of nuclear medicine is poised to make significant strides in the diagnosis and treatment of cancer, offering hope for improved outcomes and quality of life for patients.
Download free sample: https://www.pharmanucleus.com/nuclear-medicine-therapeutics-market
Contact Us:
John.M
john.m@pharmanucleus.com
Support: +44 (0)20 8470 4967
https://www.pharmanucleus.com/